Affinity Asset Advisors’s Nurix Therapeutics NRIX Stock Holding History

Affinity Asset Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.5M	Hold	967,620	–	–	1.06%	30
2026 Q1	$15M	Hold	967,620	–	–	0.77%	36
2025 Q4	$18.4M	Hold	967,620	–	–	1.05%	31
2025 Q3	$8.94M	Hold	967,620	–	–	0.78%	36
2025 Q2	$11M	Buy	967,620 +156,951	+19%	+$1.7M	1.51%	23
2025 Q1	$9.63M	Sell	810,669 -129,414	-14%	-$2.16M	0.92%	27
2024 Q4	$17.7M	Buy	940,083 +79,684	+9%	+$1.83M	2.37%	15
2024 Q3	$19.3M	Sell	860,399 -51,601	-6%	-$1.17M	2.64%	10
2024 Q2	$19M	Buy	912,000 +101,747	+13%	+$1.58M	2.19%	9
2024 Q1	$11.9M	Buy	810,253 +120,141	+17%	+$1.29M	1.47%	20
2023 Q4	$7.12M	Buy	690,112 +440,112	+176%	+$3.02M	1.3%	24
2023 Q3	$1.97M	Buy	250,000 +150,000	+150%	+$1.37M	0.55%	46
2023 Q2	$999K	Sell	100,000 -50,000	-33%	-$510K	0.35%	51
2023 Q1	$1.33M	Buy	150,000 +70,000	+88%	+$729K	0.44%	50
2022 Q4	$878K	Buy	+80,000	New	+$965K	0.34%	52

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Affinity Asset Advisors's NRIX Position: Q2 2026 in Review

Affinity Asset Advisors held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 967,620 shares worth $23.5M. The position accounts for 1.06% of the portfolio, ranked #30.

Affinity Asset Advisors first reported a position in NRIX in Q4 2022 and has held it in 15 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Affinity Asset Advisors held 967,620 shares of Nurix Therapeutics worth $23.5M as of Q2 2026.
Affinity Asset Advisors left its Nurix Therapeutics share count unchanged in Q2 2026.
Nurix Therapeutics made up 1.06% of Affinity Asset Advisors's portfolio in Q2 2026, its #30 holding.
Affinity Asset Advisors first reported a position in Nurix Therapeutics in Q4 2022 and has held it in 15 quarters since.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.